The forecasted data for the sold production of antisera and vaccines in Germany shows a steady increase from 2024 to 2028, with values growing from €2.2515 billion to €2.4294 billion. The year-on-year growth is consistent, demonstrating a stable upward trend. Specifically, the growth rate from 2024 to 2025 is approximately 2.00%, and it maintains a similar pace through to 2028. This indicates a resilient and growing sector within the pharmaceutical industry in Germany.
Looking ahead, key trends to watch include advancements in vaccine technology, particularly mRNA vaccines post-COVID-19 pandemic, the integration of AI in vaccine development, and increasing global demand for vaccines against emerging infectious diseases. These factors could potentially accelerate growth beyond current forecasts, making the sector even more crucial to both public health and the German economy.
